Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly ...

A "sub-study" of a late-stage clinical trial found the drug, obicetrapib, significantly reduced levels of a certain type of ...

It’s a truth that all clinical teams are aware of: risk mitigation is a core part of clinical trial success. But, what does ...

Early-stage study results suggest that a single shot of the company’s therapy, which works differently than GLP-1 medicines, ...

Enlicitide, which could be the first oral medication that blocks the protein PCSK9, helped cut cholesterol levels in a pair ...

The offer is the latest in a series of deals by Concentra, an investment vehicle controlled by Tang Capital Partners, to buy ...

The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...

Gene therapy experts and advocates warning of the sector’s many challenges found a receptive audience in FDA leadership at a ...

The company is one of the first to receive a “platform technology designation,” which could speed the review of certain gene ...

Breast cancer study results impressed at this year’s meeting, but raised new questions. Doctors also wrestled with how best ...

Enhertu, Datroway and other antibody-drug conjugates developed by Daiichi Sankyo have made the company a leader in a ...

Elinzanetant proved effective for managing disruptive vasomotor symptoms in women on endocrine therapy, supporting a Bayer ...